Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way
SOC 2, HITRUST, and BAAs should be treated as starting points, not trust signals. They tell you what a vendor claims about its controls. They do not tell you whether those controls are actually working today or whether the evidence behind the attestation was real.
Bridging Movement and Machine Learning: How Clinicians Can Harness AI in Practice
The true promise of AI lies not in autonomy of either the clinician or machine, but in a balanced collaboration that bolsters the strengths of each.
GLP-1s Are a $70 Billion Market — So Why Are Patients Still Getting Medical Advice From TikTok Influencers?
It’s not hard to understand why patients turn to social media for GLP-1 guidance. The healthcare system leaves a huge gap between getting a prescription and actually understanding how to use it well.
HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage
Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration's approach to healthcare costs during a recent conference address. He argued that provider taxes and state-directed payments inflate healthcare spending far beyond Medicaid and ultimately raise costs for employers and taxpayers.
Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product.